乳腺癌保乳术辅助放疗与改良根治术辅助放疗的疗效比较

目的 比较乳腺癌保乳术辅助放疗与改良根治术辅助放疗的疗效.方法 210例乳腺癌患者按治疗方法的不同,分为保乳组(110例)和改良根治术组(100例).保乳组术后放疗未行内乳照射,改良根治术组行内乳照射.比较两组术后疗效以及放疗的影响.结果 保乳组的手术时间和术中出血量均明显少于改良根治术组(P＜0.05);保乳组并发症的发生率(16.36％)与改良根治术组(22.00％)比较,差异无显著性(P＞0.05);保乳组的乳房美容优良率(68.18％)明显高于改良根治组(34.00％),差异有显著性(P＜0.01);两组术后放疗的皮肤反应分级的差异无显著性(P＞0.05);两组局部复发率、远处转移率及生存率的差异无显著性(P＞0.05).结论 乳腺癌患者保乳治疗并结合术后放疗,疗效较好,不需内乳照射,对放疗的皮肤反应、局部复发、远处转移和生存率均无影响.     

细胞周期蛋白E小干扰RNA靶向调控乳腺癌移植瘤生长的研究

细胞周期蛋白(Cyclin)E是调控细胞从G1期进入S期的一个重要蛋白,它与乳腺恶性肿瘤的生长、增殖、内分泌治疗的敏感性以及病情预后都有密切联系.已有相关文章报道在体外Cyclin E能够高效地抑制乳腺癌细胞中Cyclin E的表达,从而抑制乳腺癌细胞的生长与增殖.我们通过建立不同模式的乳腺癌移植瘤模型来观察Cyclin E在体内对于成瘤能力的不同影响,展示针对Cyclin E的RNA干扰(RNAi)技术用于基因靶向治疗的潜在价值.     

CD326在乳腺癌细胞系的表达及其与乳腺癌细胞耐药的关系

目的 探讨上皮细胞黏附分子(CD326)在乳腺癌细胞系中的表达及其与乳腺癌细胞耐药的关系.方法 流式细胞仪分析MCF-7、MCF-7/ADR及MDA-MB-231中cD326表达情况;细胞计数法(CCK-8法)检测流式细胞仪分选获得的CD326阳性和阴性细胞亚群体外对表阿霉素、多西他赛耐药情况;逆转录-聚合酶链反应(RT-PCR)检测不同细胞亚群中多药耐药基因(MDR1)及乳腺相关耐药基因(BCRP)的表达情况.结果 MCF-7/ADR中CD326的表达(31.03%)明显高于亲本株MCF-7(27.02%),MDA-MB-231中CD326的表达(33.43%)明显高于MCF-7及MCF-7/ADR;MCF-7和MDA-MB-231中CD326阳性细胞亚群对表阿霉素及低浓度多西他赛(0.25～1.0*IC50)的体外耐受性明显高于阴性细胞亚群(P＜0.01),但对高浓度多西他赛(1.5～2.0* IC50)的体外耐受性差异无统计学意义(P＞0.05);CD326阳性与阴性细胞亚群间MDR1、BCRP基因表达差异元统计学意义(P＞0.05).结论 CD326与乳腺癌化疗药物的耐药有关,其诱导耐药并不是通过经典的耐药途径.     

Inhibitory Effect of Recombinant Fibronectin Polypeptide CH50 on Invasion and Metastasis of Melanoma B16 Cells

In order to investigate the inhibitory effect and mechanism of recombinant polypeptide CH50 on invasion and metastasis of melanoma B16 cells, the recombinant polypeptide CH50 was separated and purified by ion exchange chromatographic technique. The melanoma B16 cells treated with purified CH50 were cultured in vitro, the number was counted at 4, 24, 48 and 72 h and their morphological changes were observed in order to detect their adhesion and spreading abilities. In in vivo study, the melanoma B16 cells were labeled with CFSE and treated with CH50 and then they were injected into mice via mouse-tail veins. After 5 h, the lung tissues were fixed by frozen section. Accumulation and invasion abilities of B16 cells on lung tissues were observed under the fluorescent microscopy. The results showed that the morphological character of B16 cells treated with CH50 changed greatly and the number of B16 cells treated with CH50 decreased significantly (P<0.05). The adhesion and spreading abilities of B16 cells treated with CH50 were weakened obviously and the metastasis foci on lung tissues reduced. It was concluded that the recombinant polypeptide CH50 inhibited invasion and metastasis of melanoma B16 cells on tissues and could be a prospective bio-product in tumor general therapy.